The export of Chinese patent medicine to the EU shows a restorative growth

The EU registration directive on traditional botanical drugs will be officially implemented from March 2011, which is a new regulation of EU on the registration and management of traditional botanical drugs (including Chinese traditional medicine raw materials, Chinese patent medicines and plant extracts) However, up to now, no Chinese patent medicine in China has been sold in the EU as a drug The EU registration directive on traditional botanical medicine, which was issued in March 2004, will be officially implemented in March 2011 This is a new EU regulation on the registration and management of traditional botanical medicine (including Chinese traditional medicine raw materials, Chinese patent medicine and plant extracts) But up to now, no Chinese patent medicine has been sold in EU countries as a drug Since 2007, the growth rate of China's export of Chinese patent medicines to the EU has slowed down year on year In 2009, China's export of Chinese patent medicines to the EU was 922 tons, down 17% year on year, and the export amount reached 12.43 million US dollars, down 23% year on year In 2010, with the gradual increase of international market demand, China's export of Chinese patent medicine to the EU showed a recovery growth In the first quarter, the export volume was 261 tons, an increase of 29% year-on-year, and the export volume was 3.22 million US dollars, an increase of 14% year-on-year The main export varieties of Chinese patent medicines from China to EU are other Chinese patent medicines, medicines containing artemisinin and its derivatives and cooling oil, accounting for 82%, 13% and 5% of China's exports to EU respectively At present, the main countries that China exports Chinese patent medicines to the European Union are the United Kingdom, the Netherlands, Romania, Germany and the Czech Republic In the first quarter, the number and amount of Chinese patent medicines imported from China by the Netherlands and Poland increased significantly Guangdong, Beijing, Tianjin, Shandong and Jiangsu are the main export regions of Chinese patent medicines to the EU, Shandong and Heilongjiang are the fastest growing regions, and Guangdong is the fastest declining region In 2009, there were 193 enterprises exporting Chinese patent medicines to the EU, among which 57% were state-owned enterprises, 28% were private enterprises and only 15% were foreign-funded enterprises From the first quarter's export situation, the export volume of state-owned enterprises and private enterprises to EU proprietary Chinese medicine increased by 40% and 35% respectively, while the export volume of foreign-funded enterprises decreased by 47% year on year China's main enterprises exporting Chinese patent medicines to the EU are China Pharmaceutical Healthcare Products Co., Ltd., Anhui Huishang group new energy company, Guangdong xianle pharmaceutical, Sinochem (Qingdao) Industrial Company and Shenzhen Sanjiu traditional Chinese medicine investment company Although the export of Chinese patent medicines to the EU in the first quarter of this year showed a recovery growth, at present, most of the domestic traditional Chinese medicine products are exported to the EU in the name of food and dietary supplements, which has not been changed for many years Once the "registration procedure directive of traditional botanical drugs" is strictly implemented in March 2011, China's proprietary Chinese medicines cannot be sold in EU countries with a wide market demand for traditional drugs, which will be a great loss for Chinese medicine enterprises exporting to Europe and a great challenge to the internationalization of Chinese medicine industry.